Oncology and Hematology - Global Oncology Academy

Episodes 225-240 of 386

mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib
mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib
Project Oncology®
mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib
- Charles Turck, PharmD, BCPS, BCCCP
- Neeraj Agarwal, MD, FASCO
Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access
Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access
Project Oncology®
Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access
- Rishi Sekar, MD
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Global Oncology Academy
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
- Jacob Sands, MD
- Aakesh Desai, MD, MPH
Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification
Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification
Project Oncology®
Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification
- Zachery Reichert MD, PhD
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
MinuteCE®
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
MinuteCE®
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
MinuteCE®
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
MinuteCE®
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
MinuteCE®
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
MinuteCE®
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
MinuteCE®
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
MinuteCE®
Navigating Challenges in Metastatic Gastric/GEJ Cancer Management: Advancements in Biomarker-Directed Therapies
1.25 credits 11 episodes
- Yelena Janjigian, MD
- Samuel J. Klempner, MD
1.25 credits 11 episodes
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
MinuteCE®
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
MinuteCE®
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
1.25 program credits
- Yelena Janjigian, MD
- Samuel J. Klempner, MD
1.25 program credits
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
MinuteCE®
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
1.25 program credits
- Yelena Janjigian, MD
- Samuel J. Klempner, MD
1.25 program credits
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
MinuteCE®
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits

15/11